Frederic Lamoth

Has grant

Lausanne University Hospital
Country flagSwitzerland

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Close

Epigenetic mechanisms of azole resistance in Aspergillus and Mucorales

Open Date: 2020-09-01

Close Date: 2023-08-31

Grant: Close

Modeling the Hsp90-Hsp70 Network of Antifungal Resistance in Aspergillus fumigatus

Open Date: 2016-09-01

Close Date: 2019-08-31

Grant: Close

Defining the Interaction between the Heat-Shock Proteins 90 (Hsp90) and 70 (Hsp70) and their Respective Role in Virulence and Antifungal Resistance of Aspergillus fumigatus (Follow-up of PASMP3-142746)

Open Date: 2014-03-01

Close Date: 2015-02-28

Grant: Close

Exploiting the heat-shock protein 90 (Hsp90) as a target for new antifungal therapy of invasive aspergillosis

Open Date: 2012-07-01

Close Date: 2013-06-30

Grant: Close

Role of heat-shock protein 90 (Hsp90) in Aspergillus pathogenesis and of Hsp90 inhibitors in the treatment of invasive aspergillosis

Open Date: 2011-04-01

Close Date: 2012-03-31

Articles (11)

Candida auris is an emerging yeast pathogen of major concern because of its ability to cause hospital outbreaks of invasive candidiasis and to develop resistance to antifungal drugs. A majority of C. auris isolates are resistant to fluconazole, an azole drug used for the treatment of invasive candidiasis. Mechanisms of azole resistance are multiple, including mutations in the target gene ERG11 and activation of the transcription factors Tac1b and Mrr1, which control the drug transporters Cdr1 and Mdr1, respectively. We investigated the role of the transcription factor Upc2, which is known to regulate the ergosterol biosynthesis pathway and azole resistance in other Candida spp. Genetic deletion and hyperactivation of Upc2 by epitope tagging in C. auris resulted in drastic increases and decreases in susceptibility to azoles, respectively. This effect was conserved in strains with genetic hyperactivation of Tac1b or Mrr1. Reverse transcription PCR analyses showed that Upc2 regulates ERG11 expression and also activates the Mrr1/Mdr1 pathway. We showed that upregulation of MDR1 by Upc2 could occur independently from Mrr1. The impact of UPC2 deletion on MDR1 expression and azole susceptibility in a hyperactive Mrr1 background was stronger than that of MRR1 deletion in a hyperactive Upc2 background. While Upc2 hyperactivation resulted in a significant increase in the expression of TAC1b , CDR1 expression remained unchanged. Taken together, our results showed that Upc2 is crucial for azole resistance in C. auris , via regulation of the ergosterol biosynthesis pathway and activation of the Mrr1/Mdr1 pathway. Notably, Upc2 is a very potent and direct activator of Mdr1. IMPORTANCE Candida auris is a yeast of major medical importance causing nosocomial outbreaks of invasive candidiasis. Its ability to develop resistance to antifungal drugs, in particular to azoles (e.g., fluconazole), is concerning. Understanding the mechanisms of azole resistance in C. auris is important and may help in identifying novel antifungal targets. This study shows the key role of the transcription factor Upc2 in azole resistance of C. auris and shows that this effect is mediated via different pathways, including the regulation of ergosterol biosynthesis and also the direct upregulation of the drug transporter Mdr1.

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Collaborators (3)

Thierry Calandra

Lausanne University Hospital

SWITZERLAND
View details

Dominique Sanglard

Associate Professor

Lausanne University Hospital

SWITZERLAND
View details

Anne Coste

-

FRANCE
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.